AdvanCell Strengthens Executive Leadership to Accelerate U.S. Expansion and Scale its Global Targeted Alpha Therapy Platform

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Radiology

Pharmaceutical

Oncology

Men

Research

Genetics

Consumer

Science

Clinical Trials

AdvanCell

More Like This

AdvanCell Establishes U.S. Global Headquarters and Secures Flagship Manufacturing Facility in Greater Boston to Drive Growth Strategy

AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth

AdvanCell to participate in Jefferies Global Healthcare Conference in London

AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer

AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing

AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer

AdvanCell Announces Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to Develop a Novel Peptide-Based Lead-212 Radiotherapeutic for a Gastrointestinal Cancer with Significant Medical Need

AdvanCell to Present Promising Clinical Trial Results of ADVC001, a Novel Lead-212-based PSMA-targeted Alpha Therapy for Prostate Cancer, at ESMO 2025